Impact BioMedical, INC. Shareholders' Equity
Impact BioMedical, INC. (IBO) had Shareholders' Equity of $10.77 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-07
- 2026-06-30: Stockholders' Equity Attributable to Parent $10.77M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $11.46M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $12.31M; Stockholders' Equity Attributable to Parent as first filed $12.61M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$11.81M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $10.77M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $11.46M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $12.31M 10-Q · filed 2026-08-07 | $12.61M 10-K · filed 2026-03-11 |
| 2025-09-30 | -$11.81M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | -$10.34M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $3.84M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $4.26M 10-K · filed 2026-03-11 | |
| 2024-09-30 | $31.35M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $23.37M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $24.26M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $25.22M 10-K · filed 2025-03-28 | |
| 2023-09-30 | $26.52M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $27.62M 10-Q · filed 2023-10-05 | |
| 2022-12-31 | $29.56M 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |